Could a Sugar-Blocker boost immunotherapy in tough cancers?
NCT ID NCT05913388
First seen Apr 23, 2026 · Last updated Jun 16, 2026 · Updated 11 times
Summary
This study tests whether adding an experimental drug (GB1211) to a standard immunotherapy (pembrolizumab) helps shrink tumors better than immunotherapy alone in people with advanced melanoma or head and neck cancer. About 92 adults whose cancer has spread or cannot be removed will receive either the combination or a placebo plus immunotherapy. The goal is to see if blocking a protein called galectin-3 can improve treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.